14 авг. 2019 г. · The current system of management of febrile neutropenia involves administration of prophylactic antimicrobials and hematopoietic growth factor supplements.

14 авг. 2019 г. · Hence, management of CIN remains to be a yet unmet clinical need in the delivery of cancer chemotherapy. A survey conducted by the National ...

One of the major side effects of cancer chemotherapy is myelosuppression leading to an obligate period of neutropenia.

PDF | On Aug 10, 2019, Ananya Gupta published Management of Chemotherapy Induced Neutropenia – an Unmet Clinical Need | Find, read and cite all the research ...

Neutropenia and its complications may also lead to chemotherapy dose reductions, treatment delays, or early treatment termination, compromising disease control ...

Management of chemotherapy-induced neutropenia—an unmet clinical need. Am J Biomed Sci & Res. 2019; 4(5):313-318. AJBSR.MS.ID.000823. doi:10.34297/AJBSR ...

Chemotherapy-induced neutropenia can lead to poor clinical outcomes. CIN can lead to infections, hospitalizations, mortality, and lower chemotherapy dose ...

Novel agents under investigation to help address unmet needs in the field of prophylaxis against neutropenia and other toxicities associated with chemotherapies ...

It may have short- or long-term impacts on treatment plans, which may result in unfavorable disease control and survival. Не найдено: unmet | Нужно включить: unmet

Chemotherapy-induced anemia and neutropenia may be supported with red blood cell transfusions, erythropoietin-stimulating agents, and granulocyte colony– ...